<DOC>
	<DOCNO>NCT00013533</DOCNO>
	<brief_summary>Background : - Allogeneic blood marrow stem cell transplantation ( BMT ) play important role curative treatment number pediatric malignancy . Unfortunately , success conventional allogeneic BMT limit part multiple toxicity associate myeloablative preparative regimen . - Non-myeloablative pre-transplant regimen associate less toxic side effect standard BMT . Recently , novel immunosuppressive , non-myeloablative pre-transplant chemotherapy regimen show facilitate complete donor engraftment adult trial NCI . Objectives : The primary objective protocol evaluate efficacy safety treatment approach pediatric patient hematopoietic malignancy Eligibility : Inclusion Criteria Age : Patient must great equal 5 year less 22 year age . Diagnosis : - Hodgkin Non-Hodgkin Lymphoma : Refractory disease relapse salvage regimen . - Acute Myelogenous Leukemia : History bone marrow relapse remission ( CR ) # 2 great . - Acute Lymphocytic Leukemia : History bone marrow relapse CR # 2 great ( CR # 1 Philadelphia chromosome positive prior induction failure ) . - Acute Hybrid Leukemia include mixed lineage , biphenotypic undifferentiated : History bone marrow relapse CR # 2 great ( CR # 1 Philadelphia chromosome positive prior induction failure ) . - Myelodysplastic Syndrome : RAEB RAEB-t le 10 % blast marrow blood . - Chronic Myelogenous Leukemia : Chronic phase accelerate phase le 10 % blast marrow blood . - Juvenile Myelomonocytic Leukemia : le 10 % blast marrow blood . Prior Therapy : Chemotherapy achieve criterion allow . Prior BMT allow long least day 100+ post-prior BMT , evidence GVHD , detectable residual donor chimerism . Donor : First degree related donor , HLA match ( single HLA-A B locus mismatch allow ) , weight great equal 15 kilogram , meet standard donation criterion consider . The donor prior BMT allow . ECOG Performance Status : 0 , 1 , 2. life expectancy : great 3 month . Liver Function : Serum direct bilirubin le 2.0 mg/dL serum ALT AST value less equal 2.5x upper limit normal . ( Values level may accept due malignancy . ) Renal Function : Age adjust normal serum creatinine Cr clearance great equal 60 mL/min/1.73 ( 2 ) . Pulmonary Function : DLCO great equal 50 % . Cardiac Function : LVEF great equal 45 % MUGA LVSF great equal 28 % ECHO Exclusion Criteria - Active CNS malignancy : Tumor mass CT leptomeningeal disease . ( Patients history CNS involvement current evidence CNS disease allow . ) - HIV infection , active hepatitis B C infection : HbSAg HCV seropositive elevate liver transaminase . - Fanconi Anemia . - Lactating pregnant female . Design : Pilot Study - Initial evaluation : Patient donor screen eligibility . G-CSF prim bone marrow derive stem cell collect donor . - Induction/Consolidation chemotherapy : 1 3 cycle give every 22 day depend disease response , CD4 count , toxicity . - Lymphoma : fludarabine , etoposide , doxorubicin , vincristine , cyclophohamide , prednisone , filgrastim ( EPOCH-fludarabine ) . - Leukemia MDS : Fludarabine , cytarabine , filgrastim ( FLAG ) . - Transplantation : Fludarabine cyclophosphamide administer 4 day follow bone marrow transplant . Patients remain hospitalized bone marrow recovery . Patients monitor closely NIH least 100 day post-BMT . - Post-transplant CNS prophylaxis ALL : Standard post-transplant CNS prophylaxis employ intrathecal methotrexate decrease risk CNS relapse patient ALL . - Total number recipient donor accrue 56 .</brief_summary>
	<brief_title>Pilot Study Non-Myeloablative , HLA-Matched Allogeneic Stem Cell Transplantation Pediatric Hematopoietic Malignancies</brief_title>
	<detailed_description>Background : - Allogeneic blood marrow stem cell transplantation ( BMT ) play important role curative treatment number pediatric malignancy . Unfortunately , success conventional allogeneic BMT limit part multiple toxicity associate myeloablative preparative regimen . - Non-myeloablative pre-transplant regimen associate less toxic side effect standard BMT . Recently , novel immunosuppressive , non-myeloablative pre-transplant chemotherapy regimen show facilitate complete donor engraftment adult trial NCI . Objectives : The primary objective protocol evaluate efficacy safety treatment approach pediatric patient hematopoietic malignancy Eligibility : Inclusion Criteria Age : Patient must great equal 5 year less 22 year age . Diagnosis : - Hodgkin Non-Hodgkin Lymphoma : Refractory disease relapse salvage regimen . - Acute Myelogenous Leukemia : History bone marrow relapse remission ( CR ) # 2 great . - Acute Lymphocytic Leukemia : History bone marrow relapse CR # 2 great ( CR # 1 Philadelphia chromosome positive prior induction failure ) . - Acute Hybrid Leukemia include mixed lineage , biphenotypic undifferentiated : History bone marrow relapse CR # 2 great ( CR # 1 Philadelphia chromosome positive prior induction failure ) . - Myelodysplastic Syndrome : RAEB RAEB-t le 10 % blast marrow blood . - Chronic Myelogenous Leukemia : Chronic phase accelerate phase le 10 % blast marrow blood . - Juvenile Myelomonocytic Leukemia : le 10 % blast marrow blood . Prior Therapy : Chemotherapy achieve criterion allow . Prior BMT allow long least day 100+ post-prior BMT , evidence GVHD , detectable residual donor chimerism . Donor : First degree related donor , HLA match ( single HLA-A B locus mismatch allow ) , weight great equal 15 kilogram , meet standard donation criterion consider . The donor prior BMT allow . ECOG Performance Status : 0 , 1 , 2. life expectancy : great 3 month . Liver Function : Serum direct bilirubin le 2.0 mg/dL serum ALT AST value less equal 2.5x upper limit normal . ( Values level may accept due malignancy . ) Renal Function : Age adjust normal serum creatinine Cr clearance great equal 60 mL/min/1.73 ( 2 ) . Pulmonary Function : DLCO great equal 50 % . Cardiac Function : LVEF great equal 45 % MUGA LVSF great equal 28 % ECHO Exclusion Criteria - Active CNS malignancy : Tumor mass CT leptomeningeal disease . ( Patients history CNS involvement current evidence CNS disease allow . ) - HIV infection , active hepatitis B C infection : HbSAg HCV seropositive elevate liver transaminase . - Fanconi Anemia . - Lactating pregnant female . Design : Pilot Study - Initial evaluation : Patient donor screen eligibility . G-CSF prim bone marrow derive stem cell collect donor . - Induction/Consolidation chemotherapy : 1 3 cycle give every 22 day depend disease response , CD4 count , toxicity . - Lymphoma : fludarabine , etoposide , doxorubicin , vincristine , cyclophohamide , prednisone , filgrastim ( EPOCH-fludarabine ) . - Leukemia MDS : Fludarabine , cytarabine , filgrastim ( FLAG ) . - Transplantation : Fludarabine cyclophosphamide administer 4 day follow bone marrow transplant . Patients remain hospitalized bone marrow recovery . Patients monitor closely NIH least 100 day post-BMT . - Post-transplant CNS prophylaxis ALL : Standard post-transplant CNS prophylaxis employ intrathecal methotrexate decrease risk CNS relapse patient ALL . - Total number recipient donor accrue 56 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Leukemia , Biphenotypic , Acute</mesh_term>
	<criteria>INCLUSION CRITERIA PATIENTS : Patients follow diagnosis consider : Hodgkin 's NonHodgkin 's Lymphoma : Refractory ( nonCR ) primary treatment regimen ; Refractory ( nonCR ) relapse salvage regimen . Acute Myelogenous Leukemia ( AML ) : History bone marrow relapse CR number 2 great . Acute Lymphocytic Leukemia ( ALL ) : History bone marrow relapse CR number 2 great ; complete remission # 1 Philadelphia chromosome positive prior induction failure ( subsequent induction regimen require achieve CR ) . Acute hybrid leukemia include mixed lineage , biphenotypic , undifferentiated ( AUL ) : History bone marrow relapse CR number 2 great ; Complete remission # 1 Philadelphia chromosome positive prior induction failure ( second induction regimen require achieve ( CR ) . Myelodysplastic Syndrome ( MDS ) exclude refractory anemia ( RA ) RA ring sideroblast ( RARS ) : blast less 10 % marrow blood . Chronic Myelogenous Leukemia ( CML ) : Chronic Phase ; Accelerated Phase blast less 10 % marrow blood . Juvenile Myelomonocytic Leukemia ( JMML , JCML ) : Blasts less 10 % marrow blood . Patients must great equal 4 year less 22 year age . Prior chemotherapy : Chemotherapy achieve note criterion allow . Prior autologous BMT allow . Prior allogeneic BMT allow long least day +100 postprior BMT , evidence ongoing active GVHD . Availability 5 6 antigen genotypic HLAmatched firstdegree relative donor ( single HLAA B locus mismatch allow ) . Performance status 0,1 , 2 . Life expectancy great 3 month . Liver function : serum direct bilirubin le 2.0 mg/dL , serum ALT AST value less equal 2.5 time upper limit normal . Values level may accept , discretion PI , elevation think due malignancy ( exclude acute leukemia ) . Renal function : ageadjusted normal serum creatinine creatinine clearance great equal 60 mL/min/1.73 ( 2 ) . Pulmonary function : DLCO correct hemoglobin alveolar volume great equal 50 % predict . Left ventricular function : Ejection fraction great equal 45 % MUGA shorten fraction great equal 28 % ECHO . Ability give inform consent . For patient le 18 year old legal guardian must give informed consent . Pediatric patient include age appropriate discussion order obtain verbal assent . Durable power attorney form complete ( patient great 18 year age ) . Patients must active CNS malignancy define : lymphoma ( tumor mass CT scan leptomeningeal disease ) , Leukemia ( CNS 2 CNS 3 classification ) , NB ( History CNS involvement current evidence CNS malignancy NOT exclusion ) . Patients must HIV positive . Patients must active hepatitis B C infection define seropositive hepatitis B ( HbSAg ) hepatitis C elevate liver transaminase . Female patient must lactate pregnant ( due risk fetus newborn ) . Patients must high risk inability comply transplant protocol determine principal investigator , social work , BMT team . Patients must Fanconi Anemia ( FA ) : patient MDS must negative FA test . INCLUSION CRITERIA DONOR : First degree relative genotypic identity 5 6 HLA locus ( single HLAA B locus mismatch allow ) . Weight great equal 15 kilogram . Adequate venous access peripheral apheresis , consent use temporary central venous catheter apheresis ( Cohort # 2 , possible future cell collection need ) . Ability give inform consent . For donor le 18 year age , he/she must oldest eligible donor , legal guardian must give informed consent , donor must give verbal assent , he/she must clear social work mental health specialist participate . Donor selection criterion accordance NIH/CC Department Transfusion Medicine standard . EXLCUSION CRITERIA PATIENT : Active CNS malignancy define : Lymphoma : tumor mass CT scan leptomeningeal disease Leukemia : CNS 2 CNS 3 classification NB : History CNS involvement current evidence CNS malignancy NOT exclusion . HIV positive . Active hepatitis B C infection define seropositive hepatitis B ( HbsAg ) hepatitis C elevate liver transaminase . Lactating pregnant female . High risk inability comply transplant protocol determine principal investigator , social work , BMT team . Fanconi Anemia ( FA ) : Patients MDS must negative FA test . EXCLUSION CRITERIA DONOR : History medical illness estimation PI DTM physician pose prohibitive risk donation include , limited stroke , hypertension control medication , heart disease . Individuals symptomatic angina history coronary artery bypass graft angioplasty eligible . History congenital hematologic , immunologic , metabolic disorder estimation PI pose prohibitive risk recipient . Anemia ( Hb less gm/dl ) thrombocytopenia ( le 100,000/ul ) . Lactating pregnant female . HIV positive . Seropositive hepatitis B ( HbsAg ) hepatitis C. High risk inability comply transplant protocol determine principal investigator , social work , BMT team .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>May 7, 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>Pediatric Oncology</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Childhood Cancer</keyword>
</DOC>